Ceftazidime

C difficile risk
High
Oral Bioavailability
N/A

Dosing

1 - 2 g IV q8h

Infuse over 20 minutes

Age 0-4 wk50 mg/kg/dose IV Q12H

Age 0-7 daysAge >7 days50 mg/kg/dose IV Q12H50 mg/kg/dose IV Q8H

Age 0-7 daysAge >7 days50 mg/kg/dose IV Q12H50 mg/kg/dose IV Q8H

All Infants: 50 mg/kg/dose IV Q8H

IV, IM

100 mg/mL

Reconstitute 1g vial with 9.4mL of sterile water for injection = 100 mg/mL

24H Refrigerate

0 - 10 eGFR10 - 30 eGFR30 - 50 eGFR50+ eGFR2 g IV q48 - 72h2 g IV q24h2 g IV q12h2 g IV q8h

Increase dosing interval in renal impairment

General Information

Broad gram negative coverage including Pseudomonas, generally used for nosocomial infections including post-neurosurgical meningitis, or other infections based on susceptibilities.

Notable lack of gram positive activity versus other cephalosporins.

Pregnancy: Compatible.

Breastfeeding: Compatible.

  • Allergy/rash (immediate or delayed)

  • Can cause positive Coombs, cytopenias, eosinophilia, and hepatic and renal laboratory abnormalities

Antimicrobial class: 3rd generation Cephalosporin

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.